Reviva Pharmaceuticals Holdings (RVPH) Retained Earnings (2018 - 2026)

Reviva Pharmaceuticals Holdings has reported Retained Earnings for 9 years, with the latest figure at -$187.3 million in Q1 2026.

• Quarterly Retained Earnings fell 9.74% year-over-year to -$187.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$187.3 million (down 9.74% YoY) and the FY2025 annual result came in at -$184.1 million, down 211.54% from the prior year.
• Retained Earnings eased to -$187.3 million in Q1 2026 per RVPH's latest filing, from -$184.1 million in the prior quarter.
• Over five years, Retained Earnings peaked at $165.1 million in Q4 2024 and troughed at -$187.3 million in Q1 2026.
• A 5-year average of -$78.4 million and a median of -$125.0 million in 2023 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2022 and 2023: Retained Earnings soared 261.25% in 2022, then tumbled 229.83% in 2023.
• Over 5 years, Retained Earnings stood at $103.5 million in 2022, then sank by 229.83% to -$134.4 million in 2023, then surged by 222.87% to $165.1 million in 2024, then slumped by 211.54% to -$184.1 million in 2025, then declined by 1.74% to -$187.3 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$187.3 million, -$184.1 million, and -$180.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.